EMEA-003220-PIP01-22-M01 - paediatric investigation plan
milvexian
PIPHuman
Key facts
- Active Substance
- milvexian
- Therapeutic area
- Vascular disorders
- Decision number
- P/0092/2024
- PIP number
- EMEA-003220-PIP01-22-M01
- Pharmaceutical form(s)
- Age appropriate oral dosage formulation
- Film-coated tablet
- Condition(s) / indication(s)
- Prevention of thromboembolism in patients with cardiovascular diseases
- Route(s) of administration
- Oral use
- Contact for public enquiries
Janssen Cilag International NV
Tel. +3214602111
E-mail: contact@Janssen-emea.com- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date